Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that at the Board Meeting held today i.e. on Friday, ....

Revenue declinedNet loss reportedNegative operating cash flowEBITDA margin compressionDebt to equity above the thresholdExceptional itemResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.4%Reaction day

₹29.12

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-0.5% vs market

Pharmaceuticals peers, median of 147sector-0.1%-0.3% vs sector

On the reaction day the stock moved 0.5 pts less than Nifty Microcap 250 and 0.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.4+0.1-0.5-0.1-0.3

Next day

-2.4-0.2-2.2-0.2-2.2

-1.7+0.3-2.0-0.2-1.5

+0.2+0.9-0.6+0.0+0.2

+2.2+0.8+1.5+0.0+2.2

+4.1+2.2+1.9+0.6+3.5

+4.7+3.4+1.4+1.4+3.3

15d

-3.5-0.8-2.7-2.9-0.6

+0.3+2.9-2.6+0.2+0.1

+3.2+0.8+2.4-0.5+3.7

-15.5+0.0-15.5-3.2-12.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

ANG Lifesciences India Limited's Board approved its audited financial results for Q4 FY25 and full year FY25 on May 30, 2025. Standalone revenue from operations fell sharply to ₹8,991.01 lakhs in FY25 from ₹13,136.88 lakhs in FY24, a decline of roughly 32%, while Q4 FY25 revenue dropped to ₹1,766.61 lakhs from ₹3,407.99 lakhs a year earlier. The company slipped deeper into the red, posting a standalone net loss of ₹1,034.29 lakhs (FY24: loss of ₹864.81 lakhs) and a consolidated net loss of ₹1,241.33 lakhs (FY24: loss of ₹1,014.30 lakhs), with standalone EPS at ₹(7.86). Total borrowings rose to about ₹6,780 lakhs (standalone) against equity of ₹6,680 lakhs, and operating cash flow was negative at ₹(229.27) lakhs standalone and ₹(422.67) lakhs consolidated. Statutory auditors M/s Khurana Sharma & Co. issued an unmodified opinion on the results.

Likely market impact

This is a negative outcome for shareholders — revenue shrank by over 30%, losses widened, the company is now operating with debt exceeding its equity, and cash burn from operations continues. The stock is likely to face pressure on the back of weak results, though the clean (unmodified) auditor opinion removes any immediate corporate governance overhang.